Verastem, Inc.
Industry
- Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Pharmaceuticals
- In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Latest on Verastem, Inc.
The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp
OS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so
Verastem, Inc. is plowing ahead with its combination of the RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib in solid tumors, announcing topline data and the start of a rolling regulat
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk Brings Embark Home After F